JPRAS open · 2026
Beyond the needle: psychosocial and quality-of-life outcomes following facial aesthetic injectable treatments.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michon Alain
Аннотация
BACKGROUND: Facial aesthetic injectables are commonly discussed through an anatomic and cosmetic lens. However, patients often seek treatment for reasons that exceed physical correction or enhancement, including confidence, social functioning, self-perception, and appearance-related distress.
OBJECTIVE: To identify and critically appraise evidence evaluating psychological, social, and quality-of-life outcomes following single-modality, mixed/comparative, and multimodal facial aesthetic injectable treatments.
METHODS: An evidence-based literature review was performed using PubMed, Ovid MEDLINE, and the Cochrane Library from January 2006 through June 2026. Eligible studies included adults undergoing facial aesthetic injectable treatments with botulinum toxin, hyaluronic acid fillers, biostimulatory or hybrid injectable fillers, platelet-rich plasma, polynucleotides/PDRN, or exosome-based injectables. Studies reporting psychological, social, self-esteem, appearance-related distress, social-perception, or quality-of-life outcomes were included. Studies were categorized by treatment modality and appraised using the Oxford Centre for Evidence-Based Medicine Levels of Evidence.
RESULTS: Thirty-one studies were included. Facial aesthetic injectables were generally associated with improvements in psychological, social, self-perception, appearance-related distress, social-perception, and quality-of-life outcomes. The strongest evidence was identified for single-modality botulinum toxin A, largely because of randomized controlled trials. Evidence for hyaluronic acid fillers, mixed/comparative injectable approaches, and multimodal treatments was generally positive but more heterogeneous.
CONCLUSIONS: Facial aesthetic injectables are associated with improvements in patient-reported psychosocial and quality-of-life outcomes, although the evidence remains heterogeneous. Emerging data also suggest favourable effects on observer-rated social perception. The proposed MOTIVE framework provides a pragmatic structure for integrating validated patient-reported outcome measures into routine aesthetic practice and warrants prospective evaluation.
OBJECTIVE: To identify and critically appraise evidence evaluating psychological, social, and quality-of-life outcomes following single-modality, mixed/comparative, and multimodal facial aesthetic injectable treatments.
METHODS: An evidence-based literature review was performed using PubMed, Ovid MEDLINE, and the Cochrane Library from January 2006 through June 2026. Eligible studies included adults undergoing facial aesthetic injectable treatments with botulinum toxin, hyaluronic acid fillers, biostimulatory or hybrid injectable fillers, platelet-rich plasma, polynucleotides/PDRN, or exosome-based injectables. Studies reporting psychological, social, self-esteem, appearance-related distress, social-perception, or quality-of-life outcomes were included. Studies were categorized by treatment modality and appraised using the Oxford Centre for Evidence-Based Medicine Levels of Evidence.
RESULTS: Thirty-one studies were included. Facial aesthetic injectables were generally associated with improvements in psychological, social, self-perception, appearance-related distress, social-perception, and quality-of-life outcomes. The strongest evidence was identified for single-modality botulinum toxin A, largely because of randomized controlled trials. Evidence for hyaluronic acid fillers, mixed/comparative injectable approaches, and multimodal treatments was generally positive but more heterogeneous.
CONCLUSIONS: Facial aesthetic injectables are associated with improvements in patient-reported psychosocial and quality-of-life outcomes, although the evidence remains heterogeneous. Emerging data also suggest favourable effects on observer-rated social perception. The proposed MOTIVE framework provides a pragmatic structure for integrating validated patient-reported outcome measures into routine aesthetic practice and warrants prospective evaluation.